Sun Pharma to acquire Organon in $11.75 bln all-cash deal
April 26 (Reuters) - Sun Pharmaceutical Industries SUN.NS will acquire Organon & Co OGN.N in an all‑cash deal, valuing the U.S. drugmaker at about $11.75 billion, the companies said in a joint statement on Sunday. (Reporting by Mihika Sharma in Bengaluru; Editing by Subhranshu Sahu) ((Mihika.Sharma@thomsonreuters.com;))
Recent news on Sun Pharmaceutical Industries
See all newsROI-US blue wave reshapes Asia's winners and losers: Manishi Raychaudhuri
Brief: Sun Pharma Clarifies Regarding News Report Relating To Company's Assam Facility
Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses